Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: BCRX

BioCryst Pharmaceuticals, Inc.

Healthcare | Biotechnology

No licensed closing price on file for BCRX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-1.49

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 16:49 UTC.

What BioCryst Pharmaceuticals, Inc. does

This company is a global biotechnology firm that develops and commercializes medicines for hereditary angioedema and other rare diseases. The company has built commercial infrastructure to support ORLADEYO, an oral once-daily therapy for preventing HAE attacks that it discovered and developed internally. Its business strategy leverages this established commercial platform to bring a pipeline of potential first-in-class or best-in-class oral small molecule and injectable protein therapeutics to market, pursued through both internal discovery and strategic partnerships.

Summarized from BioCryst Pharmaceuticals, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-1.49

Revenue, margins & earnings

FY2021: net loss $184M on revenue $157M$157MFY2021FY2022: net loss $247M on revenue $271M$271MFY2022FY2023: net loss $227M on revenue $331M$331MFY2023FY2024: net loss $89M on revenue $451M$451MFY2024FY2025 Net income: $264MFY2025 Taxes & interest: $77MFY2025 Operating costs: $534M$875MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-02
  • 2026-09-02DirectorAward644$6.2K
  • 2026-09-02DirectorAward1,159$11.2K
  • 2026-09-02DirectorAward1,288$12.5K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does BioCryst Pharmaceuticals, Inc. do?

This company is a global biotechnology firm that develops and commercializes medicines for hereditary angioedema and other rare diseases.

When did BCRX last file with the SEC?

BioCryst Pharmaceuticals, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-29. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 16:49 UTC. This page is also available as JSON at /api/data?ticker=BCRX and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for BCRX and 5,000+ tickers.

Create a free account — keep BCRX
For your agent
GET /api/data?ticker=BCRX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt